A New Path Begins: CGT at the Edge of Light and Change
🌞 Solstice Signals: Turning Points in Time and Medicine
Across the globe, the solstice has long marked a powerful transition — whether into the light or into reflection. From ancient observatories carved in stone to rituals aligned with the sun’s highest or lowest arc, this celestial event has inspired civilizations for millennia. It symbolized change, renewal, and the beginning of a new path.
In Cell and Gene Therapy, we find ourselves at a similar threshold. What began with the mapping of the human genome is now unfolding into real-world treatments — including the FDA’s recent approval of Casgevy, the first in vivo CRISPR-based gene editing therapy for sickle cell disease and beta-thalassemia.
Whether it's the promise of base editing, the evolution of AAV vectors, or the drive to make therapies more precise and accessible, the momentum we see today has been centuries in the making — and it’s only just beginning. In this edition, we illuminate how strategic innovation is transforming delivery, manufacturing, and possibility itself.
🔬 At the Edge of Light and Change: Redesigning AAV Vectors** for Precision and Reach
As the solstice marks a shift in the sky, researchers are reimagining the boundaries of gene delivery. This white paper explores how peptide display and DNA family shuffling are unlocking the next generation of AAV vectors — with improved targeting, lower doses, and greater clinical potential.
🧬 Where Light Meets Logic: Base Editing and AI Redefine CAR-T Engineering
When complexity demands clarity, modular platforms step forward. This blog unpacks how the Pin-point™ base editing system* — now integrated with OpenCRISPR-1 — is enabling safer, multigene-edited CAR-T therapies. With AI guiding the edits, precision becomes not just a goal, but the foundation.
📊 Mapping the New Horizon: Viral Vectors from Design to Delivery
Across the globe, the solstice signals a time to reflect and realign — and in Cell and Gene Therapy, that means refining how we deliver viral vectors with precision. This infographic maps the comprehensive AAV manufacturing workflow at Revvity: from design and scale-up to analytics and delivery.
Discover how we support your in-house capacity with tailored, scalable, and high-quality vector solutions — built for your program’s needs.
🎙 Reframing the Road: DoE strategy to double productivity and accelerate in vivo readiness
Precision-driven innovation — like our recent application of Design of Experiment (DoE) methodology — is helping reduce AAV vector manufacturing costs while boosting productivity. From discovery to delivery, we're transforming pivotal moments into faster, smarter progress. Explore how our DoE strategy doubled productivity and accelerated in vivo readiness.
🧬Guided by the Solstice: Engineering Precision at Every Step of Delivery
Modular gene editing meets evolved AAV** delivery in this in-depth feature published in GEN. Discover how Revvity’s Pin-point™* platform and collaborative vector development pipeline are helping researchers design smarter payloads and reach the right cells — with less complexity and greater clarity.
Disclaimers
For research use only. Not for use in diagnostic procedures.
*Pin-point™ Reagents & Platform: Pin-point™ base editing reagents are available for research use only and are not for diagnostic use or direct administration into humans or animals. The Pin-point™ base editing platform technology is available for clinical or diagnostic study and commercialization under a commercial license from Revvity.
**A commercial license is required for any clinical or commercial application involving AAVs developed using Revvity technologies.
Bachelor of Arts in Psychology (Major)
1moThanks for sharing